Loading…

In vivo micro computed tomography detection and decrease in amyloid load by using multifunctionalized gold nanorods: a neurotheranostic platform for Alzheimer's disease

The development and use of nanosystems is an emerging strategy for the diagnosis and treatment of a broad number of diseases, such as Alzheimer's disease (AD). Here, we developed a neurotheranostic nanosystem based on gold nanorods (GNRs) that works as a therapeutic peptide delivery system and...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials science 2021-06, Vol.9 (11), p.4178-4190
Main Authors: Morales-Zavala, Francisco, Jara-Guajardo, Pedro, Chamorro, David, Riveros, Ana L, Chandia-Cristi, America, Salgado, Nicole, Pismante, Paola, Giralt, Ernest, Sánchez-Navarro, Macarena, Araya, Eyleen, Vasquez, Rodrigo, Acosta, Gerardo, Albericio, Fernando, Alvarez R, Alejandra, Kogan, Marcelo J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development and use of nanosystems is an emerging strategy for the diagnosis and treatment of a broad number of diseases, such as Alzheimer's disease (AD). Here, we developed a neurotheranostic nanosystem based on gold nanorods (GNRs) that works as a therapeutic peptide delivery system and can be detected in vivo for microcomputed tomography (micro-CT), being a diagnostic tool. GNRs functionalized with the peptides Ang2 (a shuttle to the Central Nervous System) and D1 (that binds to the Aβ peptide, also inhibiting its aggregation) allowed detecting differences in vivo between wild type and AD mice (APPswe/PSEN1dE9) 15 minutes after a single dose by micro-CT. Moreover, after a recurrent treatment for one month with GNRs-D1/Ang2, we observed a diminution of amyloid load and inflammatory markers in the brain. Thus, this new designed nanosystem exhibits promising properties for neurotheranostics of AD.
ISSN:2047-4830
2047-4849
DOI:10.1039/d0bm01825b